Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Sell
42
SPRY Quote, Financials, Valuation and Earnings
Last price:
$14.31
Seasonality move
:
-21.39%
Day range:
$11.44 - $11.96
52-week range:
$7.55 - $18.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.63x
Volume:
1.3M
Avg. volume:
1.2M
1-year change:
37.71%
Market cap:
$1.1B
Revenue:
$30K
EPS (TTM):
-$0.51
Analysts' Opinion
-
Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.80, ARS Pharmaceuticals has an estimated upside of 155.79% from its current price of $11.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $11.65.
Fair Value
-
According to the consensus of 5 analysts, ARS Pharmaceuticals has 155.79% upside to fair value with a price target of $29.80 per share.
SPRY vs. S&P 500
-
Over the past 5 trading days, ARS Pharmaceuticals has underperformed the S&P 500 by -6.93% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ARS Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ARS Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter ARS Pharmaceuticals reported revenues of $2.1M.
Earnings Growth
-
ARS Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ARS Pharmaceuticals reported earnings per share of -$0.20.
Enterprise value:
927.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-1.20x
EV / Free cash flow:
-20.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-21.37%
Net Income Margin (TTM):
--
Return On Equity:
-22.16%
Return On Invested Capital:
-22.16%
Operating Margin:
-1051.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $2.1M | |
| Gross Profit | -- | -- | -- | -- | $2M | |
| Operating Income | -- | -$72.7M | -$60.5M | -$18M | -$21.7M | |
| EBITDA | -- | -$72.4M | -$60.5M | -$18M | -$21.7M | |
| Diluted EPS | -- | -$0.65 | -$0.51 | -$0.16 | -$0.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $244.5M | $208.8M | |
| Total Assets | -- | -- | -- | $248.6M | $217.6M | |
| Current Liabilities | -- | -- | -- | $11.2M | $16.6M | |
| Total Liabilities | -- | -- | -- | $11.3M | $16.6M | |
| Total Equity | -- | -- | -- | $237.3M | $201M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$62.4M | -$45.9M | -$12.8M | -$14.5M | |
| Cash From Investing | -- | -$113.3M | $21.7M | -$46.6M | $16.8M | |
| Cash From Financing | -- | $198.9M | $3.3M | $921K | $680K | |
| Free Cash Flow | -- | -$62.8M | -$46M | -$12.8M | -$14.6M | |
SPRY
Sector
Market Cap
$1.1B
$37.4M
Price % of 52-Week High
62.94%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
37.71%
-38.36%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$11.64
200-day SMA
Sell
Level
$12.23
Bollinger Bands (100)
Sell
Level
11.05 - 14.59
Chaikin Money Flow
Sell
Level
-4.6M
20-day SMA
Buy
Level
$11.14
Relative Strength Index (RSI14)
Buy
Level
51.98
ADX Line
Buy
Level
15.09
Williams %R
Neutral
Level
-34
50-day SMA
Sell
Level
$11.95
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
91.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (130.0018)
Buy
CA Score
(Annual)
Level (0.5489)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (43.3242)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Stock Forecast FAQ
In the current month, SPRY has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SPRY average analyst price target in the past 3 months is $29.80.
-
Where Will ARS Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that ARS Pharmaceuticals share price will rise to $29.80 per share over the next 12 months.
-
What Do Analysts Say About ARS Pharmaceuticals?
Analysts are divided on their view about ARS Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ARS Pharmaceuticals is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is ARS Pharmaceuticals's Price Target?
The price target for ARS Pharmaceuticals over the next 1-year time period is forecast to be $29.80 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SPRY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ARS Pharmaceuticals is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SPRY?
You can purchase shares of ARS Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ARS Pharmaceuticals shares.
-
What Is The ARS Pharmaceuticals Share Price Today?
ARS Pharmaceuticals was last trading at $14.31 per share. This represents the most recent stock quote for ARS Pharmaceuticals. Yesterday, ARS Pharmaceuticals closed at $11.65 per share.
-
How To Buy ARS Pharmaceuticals Stock Online?
In order to purchase ARS Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
82
EXOD alert for Mar 20
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
69
SIG alert for Mar 20
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
36
HQY alert for Mar 20
HealthEquity [HQY] is up 0.28% over the past day.
